



## **Terms of Reference**

## ATMP Education and Training Committee

	ATMP Education and Training Committee				
1. Constitution	The Advanced Medicinal Therapy Product (ATMP) board hereby resolves to establish a committee to be known as the ATMP Education and Training Committee. The committee will link with the Hematopoietic Stem Cell Transplant (HSCT)/Immune Effector Cell (IEC) Quality meeting and the Trust Education and Training Committee meeting. The committee will report to the HSCT/ IEC management meeting and the Trust Education and Training Committee as appropriate by means of joint representation and provision of committee meeting minutes. The Committee has no executive powers other than those specifically delegated within these terms of reference.				
2. Terms of	a. Purpose				
Reference	The Committee is established:				
	<ul> <li>To provide an expert developmental and discussion forum for education and training initiatives relating to Advanced Therapies across the whole Trust workforce to ensure the safe delivery of complex advanced therapies in both the commercial and research settings.</li> <li>To develop and deliver a comprehensive Trust wide Advanced Therapy Education Programme applicable and relevant to individuals and groups dependent on the appropriate level of training required</li> <li>To review, advise on and endorse the education and training elements of Trust policies, standard operating procedures, training packages and competency documents relating to ATMP delivery</li> <li>To contribute to the educational work package requirements of the</li> </ul>				
	iMATCH project				
	b. Duties				
	In relation to identifying workforce training requirements:				
	<ul> <li>To review the educational and professional development requirements of the Trust workforce in relation to ATMP delivery by undertaking a workforce scoping exercise using appropriate regulatory and guidance documents (JACIE standards, MHRA/GCP ATMP advice) as a framework</li> <li>Address the training needs from issues flagged elsewhere through trust governance processes</li> <li>To identify priority areas requiring systematic training needs analyses including the analysis of findings</li> </ul>				
	In relation to meeting training requirements:				
	<ul> <li>To provide a steer for a comprehensive and structured approach to ATMP education and training activity within the Trust, ensuring equity of access across all sites and parity across workforce groups in relation to investment and access to education and training</li> </ul>				
	To assist in audit/evaluation processes to help ensure that training				

commissioned or delivered in house is providing the skills and expertise required by the workforce and by service needs

### In relation to Trust policies

 To review, advise on and endorse education, training and supervision systems, training packages and or competency packages in relation to ATMP delivery

#### In relation to developing trainers:

 Work closely with specialist staff to ensure the continuing professional development of ATMP trainers and educators within the organisation.

# In relation to statutory reporting requirements

- To be involved as required with ensuring compliance with the JACIE essential standards in relation to advanced therapies and Immune effector cells
- To ensure compliance as required with the strategic and annual objectives of the trust in relation to education and training

### 3. Membership

The committee core membership will include:

- Chair Advanced Nurse Practitioner Advanced Therapy Research Team
- Vice Chair PTW Senior Practice Facilitator
- School of Oncology Representative
- Medical Oncology Medical representative
- Advanced/cell therapy research Senior Practice facilitator
- HSCT Senior Practice facilitator
- Advanced/cell therapy research medical representative
- Haematology Transplant Medical representative
- Haematology Transplant (PTW)

   Nursing representative
- Clinical Research Facility (CRF) Nursing representative
- The Christie Clinic (TCC) Nursing representative
- Oncology Admissions Unit medical representative
- Oncology Admissions Unit Aislinn Giles
- Oncology Admissions Unit Practice Facilitator
- Critical Care Medical representative
- Critical Care Outreach Nursing representative
- Acute Oncology Outreach Nursing representative
- Ward 4
- Ward 11 ➤ Nurse Representation
- Ward 12
- PTW pharmacy representative
- ATMP pharmacy representative

Any other staff can be asked to attend the Committee to speak to specific agenda items

#### a. Quorum

Business will only be conducted if the meeting is quorate. The committee will be quorate with 6 attendees, including the Chair or Vice

	Chair.				
	Citali.				
	b. Attendance by Members The Chair and Vice Chair of the Committee will be expected to attend 80% of the meetings over a 12 month period (baring exceptional circumstances). Other Core members will be required to attend a minimum of 60% of all meetings and be able to send a deputy to one meeting per annum.				
	c. Attendance by Others Additional attendance may be requested by invitation as necessary when relevant to specific projects or activities.				
4. Accountability and Reporting Arrangements	All committee minutes shall be reported to the HSCT/ IEC management meeting and School of Oncology Board. Any items of specific concern or risk will be reported to the ATMP Board or those which require Board approval will be the subject of a separate report.				
5. Frequency	The committee will meet a minimum of every month (twelve times per year). The chair or vice chair may at any time convene additional meetings of the committee to consider business that requires urgent attention.				
6. Authority	The Committee has decision making powers with regard to the approval of education elements of procedural documents. It is established to provide recommendations to the HSCT/ IEC management Board and School of Oncology Board on ATMP specific education matters.				
	The Committee is authorised to create sub-groups or working groups, as are necessary to fulfil its responsibilities within its terms of reference. The Committee may not delegate executive powers (unless expressly authorised by ATMP Board or the School of Oncology Board) and remains accountable for the work of any such group. The Committee is authorised to obtain outside legal or other independent professional advice and to secure the attendance of outsiders with relevant experience if it considers this necessary.				
7. Monitoring Effectiveness	The minutes of the Committee will be formally recorded and available on the Trust intranet				
8. Dissemination of information	Information on decisions made through the ATMP Education and training Committee will be communicated to the trust through formal, and informal reporting measures as appropriate.				
	Method used will include: committee reports to boards; committee minutes on the intranet and via team brief when appropriate.				
9. Review	The Committee will:  Review its Terms of Reference annually within the first quarter of the year (Apr- June) as a minimum.  Review its forward work programme annually within the first quarter of the year (Apr-June) as a minimum, this will include  A list of policies owned by the committee and their review date  A list of Standard Operating Procedures, training and/or competency documents owned by the committee and their review date  The annual audit schedule for the committee  The planned compliance review schedule for MHRA				

10. Administration	Their duties will include  Ensuring all related not less than ten we Attending the mee	d papers are available a rorking days before the detings to take minutes, provide support to the cl	and emailed to members
Date Approved	April 2019	Review Date	April 2020